Revenue growth is positive but the company's cash runway is only ~2 quarters, making a dilutive financing likely in 2H 2026. Monitor for capital raise announcements and FemBloc FDA trial updates.
Price Chart
Executive Summary
Femasys reported Q1 2026 revenue of $424,889 (+24.5% YoY) driven by FemBloc sales, with a net income of $846,100 due to $5.2M non-cash fair value gains. Core operating loss improved to $4.2M but cash burn remains high, with only $5.4M expected to fund operations into Q3 2026.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $424,889, up 24.5% YoY from $341,264
- Net income $846,100 vs net loss $5.9M YoY, but includes $5.2M non-cash gains
- Operating loss improved to $4.2M from $5.5M YoY
- Cash and equivalents $5.4M, down from $9.3M at Dec 2025
- Company expects cash to fund operations into Q3 2026
Financial Impact
Revenue growth of 24.5% adds ~$84K, but cash burn of ~$3.9M per quarter suggests need for near-term financing
Risk Factors
- Cash runway limited to Q3 2026, requiring additional financing
- Operating losses persist with negative $4.2M in the quarter
- Dependence on non-cash gains for net profitability is not sustainable
- Clinical trial and regulatory risks for FemBloc FDA approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-020059 |
| Document: ef20072749_8k.htm | 0001140361-26-020059 |
| Document: 0001140361-26-020059-index-headers.html | 0001140361-26-020059 |
| Document: 0001140361-26-020059-index.html | 0001140361-26-020059 |
| Document: 0001140361-26-020059.txt | 0001140361-26-020059 |
| 8-K Data (Synthetic) | 0001140361-26-020059 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Press Release | $1.67 | awaiting T+5 | — | $1.41 (−15.57%) |
Oct 15, 2026 11d ago | SC 13G | $1.74 $1.56 | ▼ −10.09% | ▼ −9.07% | $1.41 (−18.73%) |
Sep 29, 2026 27d ago | EFFECT | $2.09 $2.08 | ▲ +0.48% | ▲ +2.43% | $1.41 (+32.54%) |
Aug 14, 2026 10w ago | 8-K | $2.16 $2.98 | ▼ −37.96% | ▼ −39.15% | $1.41 (+34.72%) |
Aug 14, 2026 10w ago | Press Release | $2.16 $2.98 | ▲ +37.96% | ▲ +39.15% | $1.41 (−34.72%) |
Aug 11, 2026 10w ago | Insider Cluster | $2.35 $2.71 | ▲ +15.32% | ▲ +15.76% | $1.41 (−40.00%) |
Aug 7, 2026 11w ago | Press Release | $2.66 $2.29 | ▲ +13.91% | ▲ +14.31% | $1.41 (+46.99%) |
Jun 4, 2026 20w ago | 8-K | $7.14 $4.78 | ▼ −33.05% | ▼ −30.50% | $1.41 (−80.25%) |
May 13, 2026 23w ago | 8-K | $7.61 $6.75 | ▼ −11.38% | ▼ −10.66% | $1.41 (−81.48%) |
May 8, 2026 24w ago | 8-K | $8.08 $7.26 | ▼ −10.24% | ▼ −10.16% | $1.41 (−82.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers